The SF-36 and SGRQ: Validity and first look at minimum important differences in IPF

被引:203
作者
Swigris, Jeffrey J. [1 ,2 ]
Brown, Kevin K. [1 ,2 ]
Behr, Juergen [3 ]
du Bois, Roland M. [1 ,2 ]
King, Talmadge E. [4 ]
Raghu, Ganesh [5 ]
Wambold, Frederick S. [1 ,2 ]
机构
[1] Natl Jewish Hlth, Interstitial Lung Dis Program, Autoimmune Lung Ctr, Denver, CO USA
[2] Natl Jewish Hlth, Div Psychosocial Med, Denver, CO USA
[3] Univ Munich, Dept Internal Med 1, D-80539 Munich, Germany
[4] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA
[5] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA
关键词
Interstitial lung disease; Pulmonary fibrosis; Quality of life; Validity; Minimum important difference; QUALITY-OF-LIFE; IDIOPATHIC PULMONARY-FIBROSIS; INTRAINDIVIDUAL CHANGES; DISEASE; DYSPNEA; TRIAL;
D O I
10.1016/j.rmed.2009.09.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: Health-related quality of life (HRQL) is an important outcome in drug trials. Little is known about how the Short Form-36 (SF-36) and Saint George's Respiratory Questionnaire (SGRQ) perform in idiopathic pulmonary fibrosis (IPF). Objectives: To examine the validity of the SF-36 and SGRQ and to determine scores from each that would constitute a minimum important difference (MID). Methods: We analyzed data from a recently completed trial that enrolled subjects with well-defined IPF who completed the SF-36, SGRQ, and Base line/Transition Dyspnea Index at baseline and six months. We compared mean changes in HRQL scores between groups of subjects whose disease severity changed over six months according to clinical anchors (FVC, DLCO, and dyspnea). We estimated the MID for each domain by using both anchor- and distribution-based approaches. Main results: Results supported the validity of the SF-36 and SGRQ for use in longitudinal studies. Mean changes in domain scores differed significantly between subjects whose clinical status improved and those whose clinical status declined according to the anchors. MID estimates for the SF-36 ranged from 2-4 points and from 5-8 points for the SGRQ. Conclusion: In IPF, the SF-36 and SCRQ possess reasonable validity for differentiating subjects whose disease severity changes over time. More studies are needed to continue the validation process, to refine estimates of the MIDs for the SF-36 or SGRQ, and to determine if a disease-specific instrument wilt perform better than either of these. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:296 / 304
页数:9
相关论文
共 26 条
[1]  
ABRAMS D, 1976, J GERONTOL, V24, P470
[2]  
American Thoracic Society, 2000, AM J RESP CRIT CARE, V161, P646
[3]  
American Thoracic Society, 2002, AM J RESP CRIT CARE, V165, P277, DOI DOI 10.1164/ajrccm.165.2.ats01
[4]  
CRONBACH LJ, 1951, PSYCHOMETRIKA, V22, P293
[5]  
DUBOIS RM, 2008, CHEST, V134
[6]  
Hays Ron D, 2005, COPD, V2, P63
[7]  
Jones Paul W, 2005, COPD, V2, P75
[8]   THE ST-GEORGE RESPIRATORY QUESTIONNAIRE [J].
JONES, PW ;
QUIRK, FH ;
BAVEYSTOCK, CM .
RESPIRATORY MEDICINE, 1991, 85 :25-31
[9]   Health status measurement in chronic obstructive pulmonary disease [J].
Jones, PW .
THORAX, 2001, 56 (11) :880-887
[10]  
Kerlinger F.N., 1973, FDN BEHAV RES